VitaLink acquires Comprehensive Clinical Trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/usanpetkovic)
(Image: Getty/usanpetkovic)

Related tags: Clinical trial site, Women's health, Clinical trials

The clinical research site business, VitaLink Research, has acquired FL-based Comprehensive Clinical Trials, which conducts women’s health-focused Ph II-IV clinical trials.

VitaLink Research (VLR) today announced its acquisition of Comprehensive Clinical Trials (CCT).

Founded in 2004, VLR has 13 locations in the US. According to the company, headquartered in Greenville, SC, the addition expands its reach throughout the Southeast.

“The partnership with Comprehensive Clinical Trials is a critical milestone in the company’s expansion into the growing field of women’s health,”​ said Nick Wright, CEO of VitaLink Research, in a statement.

Dr. Ronald Ackerman, founder of CCT, will continue to lead the CCT business. Said Ackerman, “The strong infrastructure that VitaLink has established will enable CCT to focus exclusively on clinical research and expanding our women’s health expertise throughout the VitaLink network.”

VTL is owned by the health care investment firm, Great Point Partners (GPP), based in Greenwich, CT. The company has approximately $1bn of equity capital under management.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars